Sab Biotherapeutics Inc.
- Address
- 2100 East 54th Street North
Sponsor Overview
Specializations
Type 1 Diabetes
Clinical research activity is centered on Type 1 diabetes, with attention to newly diagnosed Stage 3 disease and the preservation of insulin-producing beta cells in the pancreas.
- Autoimmune diabetes
- Beta-cell preservation
- Newly diagnosed Stage 3 Type 1 diabetes
The sponsor’s work in this area reflects a therapeutic focus on slowing disease progression and addressing the underlying immune-mediated loss of pancreatic function.
Immunomodulation
Research interest includes immune-directed therapy aimed at altering the autoimmune process that drives destruction of pancreatic beta cells in Type 1 diabetes.
- Anti-thymocyte immunoglobulin
- Immune tolerance
- Autoimmune intervention
This therapeutic domain is closely tied to efforts to modulate pathogenic immune activity and support remaining endocrine function.
Endocrinology
The sponsor’s clinical interests extend to endocrine disease with emphasis on maintaining glycemic-related pancreatic function in individuals at an early stage of Type 1 diabetes.
- Pancreatic endocrine function
- Insulin production
- Diabetes progression
Work in this area is directed toward understanding how treatment may influence the course of endocrine decline after diagnosis.
Safety and Tolerability Research
Clinical evaluation also includes safety and tolerability considerations for treatment regimens used in people with recent-onset Type 1 diabetes.
- Treatment tolerability
- Clinical safety assessment
- Early-stage intervention
This area supports the assessment of how immune-based therapies are received in a population with active disease progression.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D) |  Austria Belgium Denmark Finland France Germany Italy Lithuania Poland Slovenia Spain | Recruiting |
Data & Insights
This sponsor works with 2 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 25 sites across their trial portfolio.
Therapeutic Focus
- 1.Nutritional and Metabolic Diseases1 trial211 other sponsors
Partnered Research Centres
25 centres- Address
- Corso Giuseppe Mazzini 18, 28100 Novara
- Address
- Boulev. De Patience Et Beajonc 2, 4000 Liège
- Address
- Janusz Korczak Avenue 12, Bult, 30173 Hanover
- Address
- Haartmaninkatu 4, 00290 Helsinki
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- Cruces Plaza S/n, 48903 Barakaldo
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Sab Biotherapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.